Tesamorelin + Ipamorelin Blend 5mg / 5mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of Tesamorelin / Ipamorelin supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF092025063

Key analytical results include:

• Ipamorelin Assay Content: 3.39 mg
• Ipamorelin Identification – Retention Time: 0.996
• Tesamorelin Assay Content: 11.22 mg
• Tesamorelin Identification – Retention Time: 0.998
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

Tesamorelin / Ipamorelin is a dual peptide research preparation frequently studied in controlled laboratory environments investigating growth hormone signalling pathways and peptide-mediated endocrine regulation.

The formulation combines two synthetic peptides that interact with the growth hormone regulatory system through distinct biochemical mechanisms.

This preparation contains 10 mg of Tesamorelin and 3 mg of Ipamorelin supplied as a high purity lyophilized peptide blend in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of the complementary mechanisms of the two peptides, this combination is commonly referenced in experimental models examining growth hormone signalling and peptide interaction dynamics.

Compound Overview

Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH), a peptide involved in the physiological signalling processes that regulate growth hormone release.

Ipamorelin is a synthetic pentapeptide that belongs to the class of growth hormone secretagogues and interacts with ghrelin receptor pathways associated with growth hormone regulation.

In research models, these two peptides are often investigated together to explore how multiple regulatory pathways influence endocrine signalling networks.

Due to their defined peptide structures and distinct receptor interaction mechanisms, Tesamorelin and Ipamorelin are frequently used in laboratory studies examining growth hormone regulatory systems.

Historical Background and Scientific Context

Scientific investigation into growth hormone regulation expanded significantly during the late twentieth century as researchers identified the complex endocrine signalling networks responsible for hormone secretion.

During this period, growth hormone releasing hormone (GHRH) and ghrelin receptor pathways were identified as central regulators of growth hormone activity.

Synthetic peptides such as Tesamorelin and Ipamorelin were subsequently developed to allow researchers to study these pathways in controlled laboratory environments.

Combination peptide models involving multiple signalling mechanisms have since become valuable tools in experimental endocrine research.

Mechanistic Focus in Research

Within experimental laboratory settings, Tesamorelin and Ipamorelin are commonly studied in relation to growth hormone regulatory pathways.

Research investigations commonly explore the compound combination in experimental models examining:

• Growth hormone signalling pathways
• GHRH receptor interaction mechanisms
• Ghrelin receptor signalling systems
• Endocrine regulatory network modelling
• Peptide-mediated hormonal signalling processes
• Comparative secretagogue research
• Hormonal regulatory feedback systems

These experimental models allow scientists to investigate molecular mechanisms that influence endocrine signalling and hormonal regulation.

Research Applications

In controlled research environments, Tesamorelin / Ipamorelin may be utilised in experimental models designed to explore endocrine signalling systems and peptide-mediated hormone regulation.

Examples of research applications include:

• Growth hormone signalling studies
• Endocrine regulatory pathway investigation
• Secretagogue interaction research
• Hormonal signalling network analysis
• Comparative peptide compound evaluation
• Intracellular signalling pathway modelling
• Controlled in vitro endocrine research

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

Verified and analysed with Liquilabs s.r.o. (Czechia)
High-purity dual research peptide blend
Validated assay content: 5.78 mg Tesamorelin and 5.21 mg Ipamorelin
Retention time identification and full COA traceability
Endotoxin levels below 0.001 EU per mg
No detectable heavy metals or microbial growth
For research use only — not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.